Thalomid offers hope for blood cancer patientsThalomid, which is also known as thalidomide, has been halted by drug company Celgene earlier than expected after the drug was shown to limit the progression of the blood cancer multiple myeloma.

It was revealed during the phase 3 trial of 270 patients that thalomid offers great benefits to patients who are suffering from blood cancer. These results prompted the decision that the trial patients not on this drug should also be given an opportunity to add thalomid to their treatment regimen.

Celgene has also recently sought approval from the FDA for Revlimid for the treatment of last-stage multiple myeloma.